|
US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
|
US7473691B2
(en)
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
DK1318997T3
(da)
*
|
2000-09-15 |
2006-09-25 |
Vertex Pharma |
Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
|
|
ATE407132T1
(de)
*
|
2000-12-05 |
2008-09-15 |
Vertex Pharma |
Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
|
|
HUP0400639A3
(en)
*
|
2000-12-21 |
2010-03-29 |
Vertex Pharma |
Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
|
|
TWI261055B
(en)
*
|
2001-03-23 |
2006-09-01 |
Bayer Corp |
Rho-Kinase Inhibitors
|
|
EP1379251B1
(en)
|
2001-04-10 |
2008-07-09 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
|
US7105667B2
(en)
*
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
|
US7138404B2
(en)
*
|
2001-05-23 |
2006-11-21 |
Hoffmann-La Roche Inc. |
4-aminopyrimidine derivatives
|
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
ES2357502T3
(es)
|
2001-09-26 |
2011-04-27 |
Pfizer Italia S.R.L. |
Derivados de aminoindazol activos como inhibidores de quinasa, procedimiento para su preparación y composiciones farmaceuticas que los contienen.
|
|
WO2003026665A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Bayer Pharmaceuticals Corporation |
2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
|
|
SE0104140D0
(sv)
*
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
WO2003055866A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
|
DE60325551D1
(de)
*
|
2002-01-10 |
2009-02-12 |
Hoffmann La Roche |
Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
KR20040084896A
(ko)
*
|
2002-02-06 |
2004-10-06 |
버텍스 파마슈티칼스 인코포레이티드 |
Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물
|
|
ATE433973T1
(de)
|
2002-03-15 |
2009-07-15 |
Vertex Pharma |
Azolylaminoazine als inhibitoren von proteinkinasen
|
|
ATE468336T1
(de)
|
2002-03-15 |
2010-06-15 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
|
EP1485100B1
(en)
*
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azinylaminoazoles as inhibitors of protein kinases
|
|
CA2480800C
(en)
|
2002-04-08 |
2008-09-23 |
Mark T. Bilodeau |
Inhibitors of akt activity
|
|
AU2003242252A1
(en)
|
2002-06-07 |
2003-12-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Bicyclic pyrimidine derivatives
|
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
|
AU2003261204A1
(en)
*
|
2002-07-23 |
2004-02-09 |
Smithkline Beecham Corporation |
Pyrazolopyrimidines as kinase inhibitors
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
EP1739087A1
(en)
*
|
2002-08-02 |
2007-01-03 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compositions useful as inhibitors of gsk-3
|
|
DE60308387T2
(de)
*
|
2002-08-02 |
2007-09-20 |
Vertex Pharmaceuticals Inc., Cambridge |
Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
|
|
WO2004022544A1
(fr)
|
2002-09-05 |
2004-03-18 |
Aventis Pharma S.A. |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
|
FR2844267B1
(fr)
*
|
2002-09-05 |
2008-02-15 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
|
AU2003255482A1
(en)
*
|
2002-10-02 |
2004-04-23 |
Merck Patent Gmbh |
Use of 4 amino-quinazolines as anti cancer agents
|
|
CA2500952C
(en)
|
2002-10-04 |
2011-04-26 |
Prana Biotechnology Limited |
Neurologically-active compounds
|
|
KR100490893B1
(ko)
*
|
2002-10-11 |
2005-05-23 |
(주) 비엔씨바이오팜 |
2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
|
|
GB0226583D0
(en)
*
|
2002-11-14 |
2002-12-18 |
Cyclacel Ltd |
Compounds
|
|
US7309701B2
(en)
|
2002-11-19 |
2007-12-18 |
Sanofi-Aventis Deutschland Gmbh |
Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
|
|
FR2847253B1
(fr)
*
|
2002-11-19 |
2007-05-18 |
Aventis Pharma Sa |
Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
|
|
US7462613B2
(en)
|
2002-11-19 |
2008-12-09 |
Sanofi-Aventis Deutschland Gmbh |
Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
|
|
ES2412273T3
(es)
|
2002-11-21 |
2013-07-10 |
Novartis Ag |
Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
|
|
WO2004072029A2
(en)
*
|
2003-02-06 |
2004-08-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyridazines useful as inhibitors of protein kinases
|
|
US7157455B2
(en)
*
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
|
WO2004087679A1
(en)
*
|
2003-04-01 |
2004-10-14 |
Aponetics Ag |
2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
|
|
US20060135541A1
(en)
*
|
2003-06-02 |
2006-06-22 |
Astrazeneca Ab |
(3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
|
|
WO2004112719A2
(en)
|
2003-06-19 |
2004-12-29 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
TWI372050B
(en)
*
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
|
CN1984660B
(zh)
|
2003-07-03 |
2010-12-15 |
美瑞德生物工程公司 |
作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
|
|
GB0315966D0
(en)
*
|
2003-07-08 |
2003-08-13 |
Cyclacel Ltd |
Compounds
|
|
NZ544756A
(en)
|
2003-07-22 |
2009-09-25 |
Astex Therapeutics Ltd |
3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
|
JP4886511B2
(ja)
|
2003-07-30 |
2012-02-29 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
|
|
EP1648875A1
(en)
*
|
2003-07-30 |
2006-04-26 |
Cyclacel Limited |
2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
|
|
US20060024690A1
(en)
*
|
2003-09-19 |
2006-02-02 |
Kao H P |
Normalization of data using controls
|
|
US7417726B2
(en)
*
|
2003-09-19 |
2008-08-26 |
Applied Biosystems Inc. |
Normalization of data using controls
|
|
US20050221357A1
(en)
*
|
2003-09-19 |
2005-10-06 |
Mark Shannon |
Normalization of gene expression data
|
|
US20050124562A1
(en)
*
|
2003-09-23 |
2005-06-09 |
Joseph Guiles |
Bis-quinazoline compounds for the treatment of bacterial infections
|
|
KR20060123164A
(ko)
|
2003-10-17 |
2006-12-01 |
아스트라제네카 아베 |
암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
|
|
JP2007513184A
(ja)
*
|
2003-12-04 |
2007-05-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼのインヒビターとして有用なキノキサリン
|
|
JP2007513955A
(ja)
*
|
2003-12-09 |
2007-05-31 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ナフチリジン誘導体およびそれらのムスカリン受容体の調節剤としての使用
|
|
US7572914B2
(en)
*
|
2003-12-19 |
2009-08-11 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
TW200530235A
(en)
|
2003-12-24 |
2005-09-16 |
Renovis Inc |
Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
|
|
WO2005077938A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
WO2005083105A2
(en)
*
|
2004-02-26 |
2005-09-09 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b)
|
|
EP1726580A4
(en)
*
|
2004-03-15 |
2008-02-13 |
Takeda Pharmaceutical |
AMINOPHNYLPROPANO ACID DERIVATIVE
|
|
US7897607B2
(en)
*
|
2004-04-07 |
2011-03-01 |
Takeda Pharmaceutical Company Limited |
Cyclic compounds
|
|
WO2005103010A2
(en)
*
|
2004-04-21 |
2005-11-03 |
Astrazeneca Ab |
Pyrazole derivatives useful for the treatment of cancer
|
|
EP1763524A1
(en)
*
|
2004-04-23 |
2007-03-21 |
Takeda San Diego, Inc. |
Indole derivatives and use thereof as kinase inhibitors
|
|
MXPA06012613A
(es)
*
|
2004-05-07 |
2007-01-31 |
Amgen Inc |
Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
|
|
US7793137B2
(en)
|
2004-10-07 |
2010-09-07 |
Cisco Technology, Inc. |
Redundant power and data in a wired data telecommunincations network
|
|
US20050255485A1
(en)
*
|
2004-05-14 |
2005-11-17 |
Livak Kenneth J |
Detection of gene duplications
|
|
WO2005113546A1
(en)
*
|
2004-05-14 |
2005-12-01 |
Vertex Pharmaceuticals, Incorporated |
Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
|
|
RS50568B8
(sr)
|
2004-05-14 |
2019-08-30 |
Millennium Pharm Inc |
Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
|
|
AU2012200416B2
(en)
*
|
2004-05-14 |
2014-07-31 |
Millennium Pharmaceuticals, Inc. |
"Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
|
|
EP1905773B1
(en)
*
|
2004-05-14 |
2012-07-18 |
Millennium Pharmaceuticals, Inc. |
Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
|
|
WO2005112923A2
(en)
*
|
2004-05-20 |
2005-12-01 |
Bayer Pharmaceuticals Corporation |
5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
|
|
EP1756673A1
(en)
*
|
2004-05-27 |
2007-02-28 |
E.I.Du pont de nemours and company |
Developer for a photopolymer protective layer
|
|
JP4990766B2
(ja)
*
|
2004-07-01 |
2012-08-01 |
シンタ ファーマシューティカルズ コーポレーション |
二置換型ヘテロアリール化合物
|
|
EP1768964A1
(en)
*
|
2004-07-06 |
2007-04-04 |
Angion Biomedica Corporation |
Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
|
|
WO2006023931A2
(en)
|
2004-08-18 |
2006-03-02 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
TW200624431A
(en)
*
|
2004-09-24 |
2006-07-16 |
Hoffmann La Roche |
Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
|
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
|
KR20070057798A
(ko)
*
|
2004-09-30 |
2007-06-07 |
티보텍 파마슈티칼즈 리미티드 |
Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
|
|
ES2380631T3
(es)
*
|
2004-09-30 |
2012-05-17 |
Tibotec Pharmaceuticals |
Pirimidinas sustituidas en posición 5 inhibidoras de VIH
|
|
BRPI0516746A
(pt)
*
|
2004-09-30 |
2008-09-23 |
Tibotec Pharm Ltd |
5-heterociclil pirimidinas para inibição de hiv
|
|
US7713973B2
(en)
|
2004-10-15 |
2010-05-11 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
EP1828165B1
(en)
*
|
2004-10-29 |
2013-03-20 |
Msd K.K. |
Novel aminopyridine derivatives having aurora a selective inhibitory action
|
|
US7491720B2
(en)
*
|
2004-10-29 |
2009-02-17 |
Banyu Pharmaceutical Co., Ltd. |
Aminopyridine derivatives having Aurora A selective inhibitory action
|
|
EP1809290A2
(en)
|
2004-11-03 |
2007-07-25 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine derivatives as ion channel modulators and methods of use
|
|
JP2008520713A
(ja)
|
2004-11-17 |
2008-06-19 |
ミイカナ セラピューティクス インコーポレイテッド |
キナーゼ阻害剤
|
|
ATE540035T1
(de)
|
2004-11-24 |
2012-01-15 |
Rigel Pharmaceuticals Inc |
Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
US20060128710A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Chih-Hung Lee |
Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
|
|
CA2588220A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Products Inc. |
Heteroaromatic derivatives useful as anticancer agents
|
|
EP2395000A1
(en)
|
2004-12-30 |
2011-12-14 |
Astex Therapeutics Limited |
Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
|
|
AU2005322855B2
(en)
|
2004-12-30 |
2012-09-20 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
|
EP1833482A4
(en)
|
2005-01-03 |
2011-02-16 |
Myriad Genetics Inc |
COMPOUNDS AND ITS THERAPEUTIC USE
|
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
|
CN101115761B
(zh)
|
2005-01-19 |
2012-07-18 |
里格尔药品股份有限公司 |
2,4-嘧啶二胺化合物的前药及其应用
|
|
AR054425A1
(es)
*
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
CN101146796A
(zh)
*
|
2005-01-26 |
2008-03-19 |
先灵公司 |
作为蛋白激酶抑制剂用于治疗癌症的3-(吲唑-5-基)-(1,2,4)三嗪衍生物及相关化合物
|
|
NZ561145A
(en)
|
2005-02-04 |
2011-02-25 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
|
EP1853602B1
(en)
*
|
2005-02-16 |
2010-07-14 |
AstraZeneca AB |
Chemical compounds
|
|
SI1853588T1
(sl)
*
|
2005-02-16 |
2008-10-31 |
Astrazeneca Ab |
Kemične spojine
|
|
MX2007011316A
(es)
*
|
2005-03-15 |
2007-11-12 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa de proteina.
|
|
JP2008534481A
(ja)
*
|
2005-03-23 |
2008-08-28 |
アストラゼネカ アクチボラグ |
インスリン様増殖因子−１受容体活性の阻害剤としての２−アゼチジニル−４−（１ｈ−ピラゾール−３−イルアミノ）ピリミジン
|
|
US7402596B2
(en)
|
2005-03-24 |
2008-07-22 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
|
SI1869032T1
(sl)
*
|
2005-04-05 |
2008-12-31 |
Astrazeneca Ab |
Pirimidinski derivati za uporabo kot sredstva proti raku
|
|
GB0507347D0
(en)
*
|
2005-04-12 |
2005-05-18 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2006233537A1
(en)
|
2005-04-14 |
2006-10-19 |
F. Hoffmann-La Roche Ag |
Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
|
|
CN101208093A
(zh)
*
|
2005-04-27 |
2008-06-25 |
阿斯利康(瑞典)有限公司 |
吡唑-嘧啶衍生物在治疗疼痛中的用途
|
|
WO2006118231A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mitsubishi Tanabe Pharma Corporation |
シアノピリジン誘導体及びその医薬としての用途
|
|
EP1885454A2
(en)
|
2005-05-04 |
2008-02-13 |
DeveloGen Aktiengesellschaft |
Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
|
|
CA2606760C
(en)
|
2005-05-04 |
2014-12-23 |
Renovis, Inc. |
Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
|
|
CN101218229A
(zh)
*
|
2005-05-05 |
2008-07-09 |
阿斯利康(瑞典)有限公司 |
吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
|
|
BRPI0610184A2
(pt)
*
|
2005-05-16 |
2012-09-25 |
Astrazeneca Ab |
composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
AU2006254840B2
(en)
|
2005-06-08 |
2012-08-02 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
EA015890B1
(ru)
|
2005-06-14 |
2011-12-30 |
Тайджен Байотекнолоджи Ко. Лтд. |
Производные пиримидина
|
|
US8193206B2
(en)
|
2005-06-14 |
2012-06-05 |
Taigen Biotechnology Co., Ltd. |
Pyrimidine compounds
|
|
EP1746096A1
(en)
|
2005-07-15 |
2007-01-24 |
4Sc Ag |
2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
|
|
AU2006279376B2
(en)
*
|
2005-08-18 |
2011-04-14 |
Vertex Pharmaceuticals Incoporated |
Pyrazine kinase inhibitors
|
|
WO2007023382A2
(en)
*
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス，インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
|
CN101316587B
(zh)
*
|
2005-09-30 |
2013-04-03 |
迈卡纳治疗股份有限公司 |
取代的吡唑化合物
|
|
CA2622352C
(en)
*
|
2005-09-30 |
2014-05-27 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
|
US8119655B2
(en)
*
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス，インコーポレイティド |
Ｐｄｅ阻害による神経新生の調節
|
|
DK1945631T3
(da)
*
|
2005-10-28 |
2012-10-22 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
|
|
EP2314289A1
(en)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
NZ567858A
(en)
*
|
2005-11-01 |
2011-08-26 |
Array Biopharma Inc |
Pyridine compounds useful as Glucokinase activators
|
|
TW200734327A
(en)
*
|
2005-11-03 |
2007-09-16 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors
|
|
EP1951716B1
(en)
*
|
2005-11-16 |
2011-05-04 |
Vertex Pharmaceuticals, Inc. |
Aminopyrimidines useful as kinase inhibitors
|
|
US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
|
US7572809B2
(en)
*
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
|
WO2007077435A1
(en)
|
2005-12-30 |
2007-07-12 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
|
US20070213319A1
(en)
*
|
2006-01-11 |
2007-09-13 |
Angion Biomedica Corporation |
Modulators of hepatocyte growth factor/c-Met activity
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
CN101415674A
(zh)
|
2006-02-16 |
2009-04-22 |
先灵公司 |
作为erk抑制剂的吡咯烷衍生物
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
PE20080145A1
(es)
*
|
2006-03-21 |
2008-02-11 |
Janssen Pharmaceutica Nv |
Tetrahidro-pirimidoazepinas como moduladores de trpv1
|
|
ES2465666T3
(es)
|
2006-03-30 |
2014-06-06 |
Janssen R&D Ireland |
Pirimidinas 5-amido-sustituidas inhibidoras del HIV
|
|
CN101437519A
(zh)
*
|
2006-03-31 |
2009-05-20 |
艾博特公司 |
吲唑化合物
|
|
EP2574340A3
(en)
|
2006-04-07 |
2013-04-17 |
Novartis AG |
Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor
|
|
US20100144693A1
(en)
|
2006-04-14 |
2010-06-10 |
Prana Biotechnology Limited |
Method of treatment of age-related macular degeneration (amd)
|
|
WO2007126126A1
(ja)
*
|
2006-04-27 |
2007-11-08 |
Banyu Pharmaceutical Co., Ltd. |
オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
|
|
CA2651862A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
ES2379661T3
(es)
*
|
2006-06-27 |
2012-04-30 |
Takeda Pharmaceutical Company Limited |
Compuestos cíclicos condensados
|
|
WO2008001115A2
(en)
|
2006-06-29 |
2008-01-03 |
Astex Therapeutics Limited |
Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
|
|
EP2043635A2
(en)
*
|
2006-06-29 |
2009-04-08 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
KR20090024270A
(ko)
*
|
2006-06-30 |
2009-03-06 |
아스트라제네카 아베 |
암 치료에 유용한 피리미딘 유도체
|
|
EP2036894A4
(en)
*
|
2006-06-30 |
2011-01-12 |
Kyowa Hakko Kirin Co Ltd |
AURORA INHIBITOR
|
|
CA2656290A1
(en)
|
2006-07-05 |
2008-01-10 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
|
AU2007283113A1
(en)
|
2006-08-08 |
2008-02-14 |
Sanofi-Aventis |
Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
|
|
US7718648B2
(en)
*
|
2006-08-09 |
2010-05-18 |
Millennium Pharmaceuticals, Inc. |
Pyridobenzazepine compounds and methods for inhibiting mitotic progression
|
|
US7635168B2
(en)
*
|
2006-08-11 |
2009-12-22 |
Hall David R |
Degradation assembly shield
|
|
JP2008081492A
(ja)
*
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
|
|
WO2008030651A1
(en)
*
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP2223925A1
(en)
*
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
GEP20135728B
(en)
|
2006-10-09 |
2013-01-25 |
Takeda Pharmaceuticals Co |
Kinase inhibitors
|
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
WO2008053812A1
(en)
*
|
2006-10-27 |
2008-05-08 |
Mitsubishi Tanabe Pharma Corporation |
Cyanopyridine derivative and medicinal use thereof
|
|
WO2008057940A1
(en)
*
|
2006-11-02 |
2008-05-15 |
Vertex Pharmaceuticals Incorporated |
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
|
|
CL2007003244A1
(es)
|
2006-11-16 |
2008-04-04 |
Millennium Pharm Inc |
Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
|
|
WO2008077086A1
(en)
*
|
2006-12-19 |
2008-06-26 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
ES2523863T3
(es)
*
|
2006-12-29 |
2014-12-02 |
Janssen R&D Ireland |
Pirimidinas 5,6-sustituidas inhibidoras del VIH
|
|
BRPI0720858B8
(pt)
*
|
2006-12-29 |
2021-05-25 |
Janssen R & D Ireland |
pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
|
|
ES2381895T3
(es)
|
2007-02-06 |
2012-06-01 |
Novartis Ag |
Inhibidores de PI 3-quinasa y métodos para su uso
|
|
US20100104567A1
(en)
|
2007-03-05 |
2010-04-29 |
Kyowa Hakko Kirin Co., Ltd. |
Pharmaceutical composition
|
|
EP2137183B1
(en)
*
|
2007-03-09 |
2011-09-28 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
WO2008112642A1
(en)
*
|
2007-03-09 |
2008-09-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
EP2134709A1
(en)
*
|
2007-03-09 |
2009-12-23 |
Vertex Pharmaceuticals, Inc. |
Aminopyridines useful as inhibitors of protein kinases
|
|
CN101675041A
(zh)
*
|
2007-03-20 |
2010-03-17 |
沃泰克斯药物股份有限公司 |
用作激酶抑制剂的氨基嘧啶类化合物
|
|
WO2008117050A1
(en)
*
|
2007-03-27 |
2008-10-02 |
Astrazeneca Ab |
Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
|
|
JP2010523700A
(ja)
*
|
2007-04-13 |
2010-07-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼインヒビターとして有用なアミノピリミジン
|
|
DK2146779T3
(en)
|
2007-04-18 |
2016-11-28 |
Pfizer Prod Inc |
Sulfonylamid derivatives to treat abnormal cell growth.
|
|
WO2008129255A1
(en)
*
|
2007-04-18 |
2008-10-30 |
Astrazeneca Ab |
5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
|
|
CN101801959A
(zh)
*
|
2007-05-02 |
2010-08-11 |
沃泰克斯药物股份有限公司 |
可用作激酶抑制剂的氨基嘧啶类化合物
|
|
CN101679378A
(zh)
|
2007-05-02 |
2010-03-24 |
沃泰克斯药物股份有限公司 |
用作激酶抑制剂的噻唑和吡唑
|
|
AU2008247595A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
US20100137398A1
(en)
*
|
2007-05-04 |
2010-06-03 |
Novartis Ag |
Use of hdac inhibitors for the treatment of gastrointestinal cancers
|
|
UA99459C2
(en)
*
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
AU2008257044A1
(en)
*
|
2007-05-24 |
2008-12-04 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
|
KR101294731B1
(ko)
*
|
2007-06-04 |
2013-08-16 |
삼성디스플레이 주식회사 |
어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
|
|
JP2010529193A
(ja)
*
|
2007-06-11 |
2010-08-26 |
ミイカナ セラピューティクス インコーポレイテッド |
置換ピラゾール化合物
|
|
EP2178563A2
(en)
*
|
2007-07-06 |
2010-04-28 |
OSI Pharmaceuticals, Inc. |
Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
|
|
WO2009007753A2
(en)
*
|
2007-07-11 |
2009-01-15 |
Astrazeneca Ab |
4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
|
|
US8415340B2
(en)
*
|
2007-07-25 |
2013-04-09 |
Bristol-Myers Squibb Company |
Triazine kinase inhibitors
|
|
WO2009013545A2
(en)
*
|
2007-07-26 |
2009-01-29 |
Astrazeneca Ab |
Chemical compounds
|
|
TW200906818A
(en)
*
|
2007-07-31 |
2009-02-16 |
Astrazeneca Ab |
Chemical compounds
|
|
AR067762A1
(es)
|
2007-07-31 |
2009-10-21 |
Vertex Pharma |
Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2009027736A2
(en)
*
|
2007-08-27 |
2009-03-05 |
Astrazeneca Ab |
2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
|
|
ES2393824T3
(es)
|
2007-09-21 |
2012-12-28 |
Array Biopharma, Inc. |
Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus
|
|
PT2214487E
(pt)
|
2007-10-11 |
2014-02-20 |
Glaxosmithkline Llc |
Novos inibidores de seh e sua utilização
|
|
JP5562865B2
(ja)
|
2007-12-17 |
2014-07-30 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
|
|
US20090270418A1
(en)
*
|
2008-01-09 |
2009-10-29 |
Marianne Sloss |
Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
|
|
WO2009097995A1
(de)
*
|
2008-02-07 |
2009-08-13 |
Sanofi-Aventis |
Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
NZ587504A
(en)
|
2008-02-21 |
2012-09-28 |
Merck Sharp & Dohme |
Benzopyrazole derivatives as ERK inhibitors
|
|
JP5411152B2
(ja)
*
|
2008-02-22 |
2014-02-12 |
Ｍｓｄ株式会社 |
オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
|
|
DK2268635T3
(en)
|
2008-04-21 |
2015-09-14 |
Taigen Biotechnology Co Ltd |
Heterocyclic Compounds
|
|
WO2010011411A1
(en)
|
2008-05-27 |
2010-01-28 |
The Trustees Of Columbia University In The City Of New York |
Systems, methods, and media for detecting network anomalies
|
|
CN102119157A
(zh)
*
|
2008-06-11 |
2011-07-06 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症和骨髓增生性疾病的三环2，4-二氨基-l，3，5-三嗪衍生物
|
|
UY31968A
(es)
|
2008-07-09 |
2010-01-29 |
Sanofi Aventis |
Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
|
|
UA101676C2
(uk)
*
|
2008-07-31 |
2013-04-25 |
Дженентек, Инк. |
Піримідинові сполуки, композиції і способи застосування
|
|
AU2009288200A1
(en)
*
|
2008-09-03 |
2010-03-11 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
|
MY156789A
(en)
*
|
2008-09-05 |
2016-03-31 |
Celgene Avilomics Res Inc |
Algorithm for designing irreversible inhibitors
|
|
CA2737388C
(en)
*
|
2008-09-15 |
2017-07-11 |
Peter Walter |
Methods and compositions for modulating ire1, src, and abl activity
|
|
JP2012504157A
(ja)
*
|
2008-09-30 |
2012-02-16 |
アストラゼネカ アクチボラグ |
複素環式ｊａｋキナーゼ阻害剤
|
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
|
WO2010056758A1
(en)
*
|
2008-11-12 |
2010-05-20 |
Yangbo Feng |
Quinazoline derivatives as kinase inhibitors
|
|
TW201021855A
(en)
|
2008-11-13 |
2010-06-16 |
Taigen Biotechnology Co Ltd |
Lyophilization formulation
|
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
ES2422263T3
(es)
*
|
2008-12-19 |
2013-09-10 |
Nerviano Medical Sciences Srl |
Pirazoles bicíclicos como inhibidores de la proteinquinasa
|
|
MX2011006725A
(es)
|
2008-12-22 |
2011-09-15 |
Millennium Pharm Inc |
Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
|
|
WO2010072155A1
(zh)
*
|
2008-12-26 |
2010-07-01 |
复旦大学 |
一种嘧啶类衍生物及其制备方法和用途
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
PL2401267T3
(pl)
*
|
2009-02-27 |
2014-06-30 |
Ambit Biosciences Corp |
Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
|
|
CA2660962A1
(en)
|
2009-03-31 |
2010-09-30 |
Astellas Pharma Inc. |
Novel pharmaceutical composition for treatment of schizophrenia
|
|
US8399663B2
(en)
|
2009-04-03 |
2013-03-19 |
Astellas Pharma Inc. |
Salt of 1,3,5-triazine-2,4,6-triamine derivative
|
|
JO3635B1
(ar)
|
2009-05-18 |
2020-08-27 |
Millennium Pharm Inc |
مركبات صيدلانية صلبة وطرق لانتاجها
|
|
EP2440050A4
(en)
*
|
2009-06-08 |
2013-04-03 |
California Capital Equity Llc |
TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
|
|
BRPI1010887A2
(pt)
*
|
2009-06-08 |
2016-12-27 |
California Capital Equity Llc |
derivados de triazina e suas aplicações terapêuticas.
|
|
JP2012529517A
(ja)
*
|
2009-06-09 |
2012-11-22 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
ベンジル置換トリアジン誘導体類及びそれらの治療応用
|
|
JP2012529519A
(ja)
*
|
2009-06-09 |
2012-11-22 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
スチリル−トリアジン誘導体類及びそれらの治療応用
|
|
KR101457027B1
(ko)
*
|
2009-06-09 |
2014-10-31 |
캘리포니아 캐피탈 에쿼티, 엘엘씨 |
트리아진 유도체와 이들의 치료적 용도
|
|
AU2010258825B2
(en)
*
|
2009-06-09 |
2014-08-21 |
Nantbio, Inc. |
Ureidophenyl substituted triazine derivatives and their therapeutical applications
|
|
US20120172384A1
(en)
*
|
2009-06-18 |
2012-07-05 |
Mihiro Sunose |
Heterocyclylaminopyrimidines as kinase inhibitors
|
|
TWI468402B
(zh)
*
|
2009-07-31 |
2015-01-11 |
必治妥美雅史谷比公司 |
降低β－類澱粉生成之化合物
|
|
US8637525B2
(en)
|
2009-07-31 |
2014-01-28 |
Bristol-Myers Squibb Company |
Compounds for the reduction of beta-amyloid production
|
|
KR20120060207A
(ko)
|
2009-08-26 |
2012-06-11 |
사노피 |
신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
|
|
IN2012DN02534A
(enExample)
|
2009-09-16 |
2015-08-28 |
Avila Therapeutics Inc |
|
|
KR102109626B1
(ko)
*
|
2009-11-13 |
2020-05-12 |
인튜어티브 서지컬 오퍼레이션즈 인코포레이티드 |
여분의 닫힘 메커니즘을 구비한 단부 작동기
|
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
|
US20110269244A1
(en)
|
2009-12-30 |
2011-11-03 |
Petter Russell C |
Ligand-directed covalent modification of protein
|
|
SA111320200B1
(ar)
*
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
|
|
CN102770024A
(zh)
|
2010-02-19 |
2012-11-07 |
米伦纽姆医药公司 |
4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2571359A4
(en)
*
|
2010-05-20 |
2013-10-23 |
Merck Sharp & Dohme |
NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
|
|
CN103003264B
(zh)
|
2010-05-21 |
2014-08-06 |
切米利亚股份公司 |
嘧啶衍生物
|
|
HUE029196T2
(en)
|
2010-06-04 |
2017-02-28 |
Hoffmann La Roche |
Aminoprimidine derivatives as LRRK2 modulators
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
WO2012013728A1
(en)
|
2010-07-29 |
2012-02-02 |
Oryzon Genomics S.A. |
Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
|
|
CN103298805A
(zh)
*
|
2010-09-01 |
2013-09-11 |
埃姆比特生物科学公司 |
喹唑啉化合物及其使用方法
|
|
WO2012030913A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
US20130296363A1
(en)
*
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
US20120053176A1
(en)
*
|
2010-09-01 |
2012-03-01 |
Ambit Biosciences Corp. |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
US8633209B2
(en)
|
2010-09-01 |
2014-01-21 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
|
WO2012030914A1
(en)
*
|
2010-09-01 |
2012-03-08 |
Ambit Boisciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
EP2611793A1
(en)
*
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
WO2012059932A1
(en)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
|
|
SG189043A1
(en)
|
2010-11-10 |
2013-05-31 |
Hoffmann La Roche |
Pyrazole aminopyrimidine derivatives as lrrk2 modulators
|
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8809325B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
EP2683703B1
(de)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2012120058A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
CA2830129C
(en)
|
2011-03-24 |
2016-07-19 |
Chemilia Ab |
Novel pyrimidine derivatives
|
|
MX2014002208A
(es)
*
|
2011-08-25 |
2014-05-28 |
Hoffmann La Roche |
Inhibidores de serina/treonina quinasa.
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
MD20140023A2
(ro)
|
2011-09-22 |
2014-06-30 |
Pfizer Inc. |
Derivaţi de pirolpirimidină şi purină
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2771337B1
(en)
|
2011-09-27 |
2017-08-02 |
Novartis AG |
3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh
|
|
CA2856291C
(en)
|
2011-11-17 |
2020-08-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
|
KR20140103972A
(ko)
|
2011-12-22 |
2014-08-27 |
에프. 호프만-라 로슈 아게 |
세린/트레오닌 키나아제 억제제로서의 2,4-다이아민-피리미딘 유도체
|
|
CA2864825C
(en)
*
|
2012-02-17 |
2021-01-26 |
Abbvie Inc. |
Diaminopyrimidines useful as inhibitors of the human respiratory syncytial virus (rsv)
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
TWI485146B
(zh)
*
|
2012-02-29 |
2015-05-21 |
Taiho Pharmaceutical Co Ltd |
Novel piperidine compounds or salts thereof
|
|
AU2013205306B2
(en)
|
2012-03-16 |
2015-09-17 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
|
IN2014KN02601A
(enExample)
|
2012-04-24 |
2015-05-08 |
Vertex Pharma |
|
|
JP6197031B2
(ja)
*
|
2012-05-24 |
2017-09-13 |
セルゾーム リミティッド |
Ｔｙｋ２阻害剤としてのヘテロシクリルピリミジン類似体
|
|
CA2880896C
(en)
|
2012-06-26 |
2021-11-16 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
|
CN104662014B
(zh)
*
|
2012-07-10 |
2017-02-22 |
阿雷斯贸易股份有限公司 |
嘧啶吡唑基衍生物
|
|
HUE032635T2
(en)
*
|
2012-09-19 |
2017-10-30 |
Taiho Pharmaceutical Co Ltd |
For oral administration of pharmaceutical compositions having improved elution and / or absorbance
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
CN103202843B
(zh)
*
|
2012-12-31 |
2015-04-29 |
刘强 |
一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
|
|
CN103191120B
(zh)
*
|
2012-12-31 |
2015-11-25 |
刘强 |
一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗肿瘤的药物中的用途
|
|
CN103059002B
(zh)
*
|
2012-12-31 |
2015-04-22 |
中山大学 |
具有Aurora激酶抑制活性的嘧啶衍生物及其制备方法以及应用
|
|
CN103910716A
(zh)
*
|
2013-01-07 |
2014-07-09 |
华东理工大学 |
2,4-二取代-环烷基[d]嘧啶类化合物及其用途
|
|
SMT202100687T1
(it)
|
2013-03-12 |
2022-01-10 |
Vertex Pharma |
Inibitori della dna-pk
|
|
WO2014141104A1
(en)
|
2013-03-14 |
2014-09-18 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
EP3842424B1
(en)
|
2013-03-15 |
2024-12-11 |
The Trustees of Columbia University in the City of New York |
Map kinase modulators and uses thereof in the tretament of tauopathies
|
|
WO2014153509A1
(en)
|
2013-03-22 |
2014-09-25 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
|
WO2015003355A2
(en)
*
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
CA2938626A1
(en)
|
2013-07-26 |
2015-01-29 |
John Rothman |
Compositions to improve the therapeutic benefit of bisantrene
|
|
WO2015028848A1
(en)
*
|
2013-09-02 |
2015-03-05 |
Piramal Enterprises Limited |
Bicyclic heterocyclic compounds as multi-kinase inhibitors
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
ES2705342T3
(es)
|
2013-10-17 |
2019-03-22 |
Vertex Pharma |
Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
|
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
AU2014337122B2
(en)
|
2013-10-18 |
2019-01-03 |
Dana-Farber Cancer Institute, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
|
HUE050761T2
(hu)
|
2014-01-01 |
2021-01-28 |
Medivation Tech Llc |
Vegyületek és alkalmazási eljárások
|
|
WO2015136538A1
(en)
|
2014-03-13 |
2015-09-17 |
Neuroderm Ltd |
Dopa decarboxylase inhibitor compositions
|
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
|
WO2015148868A1
(en)
*
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
RS60878B1
(sr)
|
2014-04-04 |
2020-11-30 |
Iomet Pharma Ltd |
Derivati indola za upotrebu u medicini
|
|
US20170165230A1
(en)
|
2014-04-09 |
2017-06-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
CN105367555B
(zh)
*
|
2014-08-07 |
2019-06-25 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
|
MX2017003181A
(es)
|
2014-10-13 |
2017-07-20 |
Yuhan Corp |
Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico.
|
|
CN107250116B
(zh)
|
2014-12-23 |
2020-10-27 |
艾士盟医疗公司 |
3,5-二氨基吡唑激酶抑制剂
|
|
EP3236959B1
(en)
|
2014-12-23 |
2025-09-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
US10227343B2
(en)
*
|
2015-01-30 |
2019-03-12 |
Vanderbilt University |
Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
CA2982890C
(en)
|
2015-04-17 |
2023-08-22 |
Ludwig Institute For Cancer Research Ltd |
Plk4 inhibitors
|
|
JP6692836B2
(ja)
|
2015-05-28 |
2020-05-13 |
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー |
Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
|
|
JP2018135268A
(ja)
*
|
2015-06-05 |
2018-08-30 |
大日本住友製薬株式会社 |
新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
|
|
JP2018524292A
(ja)
|
2015-07-21 |
2018-08-30 |
ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
オーロラキナーゼインヒビターと化学療法剤の投与
|
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
CN110946865B
(zh)
|
2015-12-10 |
2024-01-26 |
Ptc医疗公司 |
用于治疗亨廷顿病的方法
|
|
CN105399695B
(zh)
*
|
2015-12-11 |
2019-04-19 |
浙江大学 |
三嗪类化合物及其制备方法和用途
|
|
CN105384702B
(zh)
*
|
2015-12-11 |
2018-04-10 |
浙江大学 |
三取代均三嗪类化合物及其制备方法
|
|
CN105503754B
(zh)
*
|
2015-12-11 |
2017-11-17 |
浙江大学 |
2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
|
|
EP3390387B1
(en)
|
2015-12-18 |
2021-11-17 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
|
JP6968810B2
(ja)
|
2016-03-14 |
2021-11-17 |
アファレント ファーマシューティカルズ インコーポレイテッド |
ピリミジンおよびそのバリアント、ならびにそのための使用
|
|
US10662162B2
(en)
|
2016-03-25 |
2020-05-26 |
Afferent Pharmaceuticals, Inc. |
Pyrimidines and variants thereof, and uses therefor
|
|
WO2017189822A1
(en)
|
2016-04-28 |
2017-11-02 |
Theravance Biopharma R&D Ip, Llc |
Pyrimidine compounds as jak kinase inhibitors
|
|
WO2017207534A1
(en)
|
2016-06-03 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituted heteroarylbenzimidazole compounds
|
|
EP3518931A4
(en)
|
2016-09-27 |
2020-05-13 |
Vertex Pharmaceuticals Incorporated |
METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
|
|
US10858319B2
(en)
|
2016-10-03 |
2020-12-08 |
Iomet Pharma Ltd. |
Indole derivatives for use in medicine
|
|
US10968227B2
(en)
*
|
2016-11-08 |
2021-04-06 |
Vanderbilt University |
Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
|
CN108239071B
(zh)
*
|
2016-12-27 |
2020-12-04 |
沈阳药科大学 |
酰胺及硫代酰胺类衍生物及其制备方法和应用
|
|
FR3064275B1
(fr)
|
2017-03-21 |
2019-06-07 |
Arkema France |
Procede de chauffage et/ou climatisation d'un vehicule
|
|
WO2018219725A1
(en)
|
2017-05-30 |
2018-12-06 |
Basf Se |
Pyridine and pyrazine compounds
|
|
EP3634953B1
(en)
|
2017-06-05 |
2024-01-03 |
PTC Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
MX2019015578A
(es)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics Inc |
Metodos para tratar la enfermedad de huntington.
|
|
CN111163838B
(zh)
|
2017-06-28 |
2023-03-28 |
Ptc医疗公司 |
用于治疗亨廷顿氏病的方法
|
|
WO2019001572A1
(zh)
|
2017-06-30 |
2019-01-03 |
北京泰德制药股份有限公司 |
Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
|
|
KR102563325B1
(ko)
*
|
2017-06-30 |
2023-08-03 |
베이징 타이드 파마슈티컬 코퍼레이션 리미티드 |
Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
|
|
WO2019000683A1
(zh)
|
2017-06-30 |
2019-01-03 |
北京泰德制药股份有限公司 |
Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
|
|
US20200199136A1
(en)
*
|
2017-08-28 |
2020-06-25 |
Acurastem Inc. |
Pikfyve kinase inhibitors
|
|
EP3675860B1
(en)
*
|
2017-08-28 |
2023-03-08 |
Zhihong, Chen |
Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
|
|
PT3672965T
(pt)
|
2017-10-27 |
2022-09-29 |
Theravance Biopharma R&D Ip Llc |
Composto de pirimidina como inibidor de jak cinase
|
|
CN111247139A
(zh)
*
|
2017-11-23 |
2020-06-05 |
艾克斯生物医药股份有限公司 |
嘧啶衍生物作为原肌球蛋白受体激酶a(trka)抑制剂
|
|
WO2019113311A1
(en)
|
2017-12-06 |
2019-06-13 |
Ludwig Institute For Cancer Research Ltd |
Methods of treating cancer with plk4 inhibitors
|
|
KR20200143376A
(ko)
|
2018-03-13 |
2020-12-23 |
샤이어 휴먼 지네틱 테라피즈 인크. |
혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
|
|
JP7399870B2
(ja)
|
2018-03-27 |
2023-12-18 |
ピーティーシー セラピューティクス， インコーポレイテッド |
ハンチントン病を処置するための化合物
|
|
JP7590185B2
(ja)
*
|
2018-06-25 |
2024-11-26 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
|
|
KR20210038845A
(ko)
|
2018-06-27 |
2021-04-08 |
피티씨 테라퓨틱스, 인크. |
헌팅턴병 치료를 위한 헤테로아릴 화합물
|
|
EP3814360B8
(en)
|
2018-06-27 |
2024-11-06 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
PL3814357T3
(pl)
|
2018-06-27 |
2024-09-16 |
Ptc Therapeutics, Inc. |
Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
|
|
WO2020033919A1
(en)
|
2018-08-10 |
2020-02-13 |
Diapin Therapeutics, Llc |
Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
|
|
CN111511738B
(zh)
*
|
2018-11-30 |
2023-01-20 |
江苏豪森药业集团有限公司 |
杂芳类衍生物调节剂、其制备方法和应用
|
|
AU2019413694B2
(en)
|
2018-12-28 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 and uses thereof
|
|
AR118767A1
(es)
|
2019-04-24 |
2021-10-27 |
Theravance Biopharma R&D Ip Llc |
Pirimidinas sustituidas como inhibidores de jak y su uso para el tratamiento de enfermedades inflamatorias o autoinmunes cutáneas
|
|
ES2974577T3
(es)
|
2019-04-24 |
2024-06-27 |
Theravance Biopharma R&D Ip Llc |
Compuestos éster y carbonato de pirimidina como inhibidores de JAK quinasa
|
|
CN114245794B
(zh)
|
2019-05-13 |
2024-09-13 |
Ptc医疗公司 |
用于治疗亨廷顿氏病的化合物
|
|
KR20220042159A
(ko)
*
|
2019-08-01 |
2022-04-04 |
인테그랄 바이오사이언스 피브이티. 엘티디. |
키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도
|
|
WO2021055589A1
(en)
|
2019-09-18 |
2021-03-25 |
Shire Human Genetic Therapies, Inc. |
Heteroaryl plasma kallikrein inhibitors
|
|
ES2987744T3
(es)
|
2019-09-18 |
2024-11-18 |
Takeda Pharmaceuticals Co |
Inhibidores de calicreína plasmática y usos de los mismos
|
|
CN110483493A
(zh)
*
|
2019-09-19 |
2019-11-22 |
广东工业大学 |
一种二唑类衍生物及其制备方法和应用
|
|
KR20220140515A
(ko)
|
2020-01-13 |
2022-10-18 |
버지 애널리틱스, 인크. |
치환된 피라졸로-피리미딘 및 그의 용도
|
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
|
US11844754B2
(en)
|
2020-11-17 |
2023-12-19 |
Neuroderm, Ltd. |
Methods for treatment of Parkinson's disease
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
EP4308564A1
(en)
*
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Polycyclic inhibitors of plasma kallikrein
|
|
WO2022204683A1
(en)
*
|
2021-03-24 |
2022-09-29 |
Athos Therapeutics, Inc. |
Small molecules for the treatment of kinase-related diseases
|
|
CN117355304A
(zh)
*
|
2021-03-26 |
2024-01-05 |
住友制药肿瘤公司 |
Alk-5抑制剂及其用途
|
|
US20240197729A1
(en)
*
|
2021-03-26 |
2024-06-20 |
Sumitomo Pharma Oncology, Inc. |
ALK-5 Inhibitors and Uses Thereof
|
|
CN117794529B
(zh)
|
2021-05-11 |
2025-02-11 |
欧瑞克制药公司 |
Polo样激酶4抑制剂
|
|
KR20240046167A
(ko)
|
2021-06-28 |
2024-04-08 |
블루프린트 메디신즈 코포레이션 |
Cdk2 저해제
|
|
KR102692529B1
(ko)
*
|
2021-07-01 |
2024-08-08 |
한국원자력의학원 |
Mastl-pp2a를 표적화하는 암의 예방 또는 치료용 약학적 조성물
|
|
CN116354938B
(zh)
*
|
2021-12-28 |
2024-02-20 |
沈阳药科大学 |
一类喹唑啉衍生物与其类似物的制备方法及应用
|
|
CN114276302B
(zh)
*
|
2022-01-11 |
2023-07-25 |
山东百启生物医药有限公司 |
一种制备2,4-二氨基喹唑啉衍生物的方法
|
|
CN116813595B
(zh)
*
|
2022-03-28 |
2025-07-18 |
上海医药工业研究院有限公司 |
喹唑啉类衍生物、其制备方法、药物组合物及应用
|
|
WO2024003773A1
(en)
|
2022-07-01 |
2024-01-04 |
Pfizer Inc. |
2,7-naphthyridine compounds as mastl inhibitors
|
|
CN117736198A
(zh)
*
|
2022-09-21 |
2024-03-22 |
科辉智药生物科技(深圳)有限公司 |
大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
|
|
CN115403568B
(zh)
*
|
2022-09-21 |
2023-09-29 |
中山大学 |
一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用
|
|
CN121001717A
(zh)
*
|
2023-02-23 |
2025-11-21 |
冰洲石生物科技公司 |
作为cdk2抑制剂的新型大环氨基吡唑化合物
|
|
US12161612B2
(en)
|
2023-04-14 |
2024-12-10 |
Neuroderm, Ltd. |
Methods and compositions for reducing symptoms of Parkinson's disease
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|